The HFSA Virtual Board Certification Review 2020 will be comprised of renowned heart failure experts presenting curriculum that has been tailored to the actual ABIM examination. Presentations will be augmented by board-review type questions using an audience response system, providing an interactive experience for attendees. The course will take place over three (3) days (July 24, July 31, August 1) and include pre-recorded ondemand webinars.
- Co-Chairs: Akshay Desai, MD, MPH, FHFSA; Jonathan Rich, MD, FHFSA; Nancy Sweitzer, MD, PhD, FHFSA
The program will be made up of the following components to allow attendees greater access to the content.
Available in early July, this pre-recorded, ondemand webinar series features the basics and can be completed at the attendee's convenience.
Three, non-consecutive days of livestreamed sessions (July 24, July 31, August 1) delivered by top experts in the field. Attendees should anticipate being online throughout to receive maximum value from these live sessions. Explore full agenda below!
Post-meeting, virtual livestream Q&A panel taking place in September to allow attendees to ask last-minute questions prior to the examination in October.
Upon completion of the activity, participants will demonstrate improved competence and ability to:
For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:
- Identify gaps in knowledge about advanced heart failure and transplant cardiology
- Focus study efforts on filling identified knowledge gaps
- Practice for the certification examination with ABIM-style multiple-choice test questions
For Clinical Practice:
- Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
- Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
- Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
- Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
- Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
- Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
- Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
- Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device
Concise presentations by national experts will focus on blueprint content and will be augmented by board-reviewtype questions posed using an audience-response system.
Each webinar is 30 minutes in length. This series will be available to all registered attendees in early July, and will be available ondemand to be completed at the attendee's convenience.
|Heart Failure Epidemiology and Risk Factors||Sadiya Kahn|
|Pathophysiology I: Cellular and Energetic Considerations||Daniel Burkhoff|
|Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations||Daniel Burkhoff|
|Diagnosis and Clinical Assessment||Mark Drazner|
|Device Therapy in Heart Failure||Liviu Klein|
|Cardio-Oncology for the HF boards||Anju Nohria|
|Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards||Jon Lomasney|
These sessions will be livestreamed on the following days: July 24, July 31, August 1. Scroll down to see the full agenda, and look below for the basic outline on days and topics. Attendees will be able to download session slides during the meeting. Attendees should anticipate being online for the full sessions outlined under the Livestream Sessions to maximize their learning potential. However, if a livestream session must be missed due to other circumstances, all livestream sessions will be available for attendees to download and access approximately two weeks after the meeting concludes on August 1.
All sessions below are listed in Eastern Standard Time.
Day #1 | Friday, July 24
3:00 PM – 6:00 PM EST
|Day #2 | Friday, July 31||11:00 AM – 6:00 PM EST||
|Day #3 | Saturday, August 1||11:00 AM – 5:45 PM EST||
Post-meeting, virtual livestream Q&A panel taking place in September to allow attendees to ask last-minute questions prior to the examination in October. Faculty "Office Hours" will be live; therefore, attendees are encouraged to be available during these hours to engage in Q&A as final prep for the exam. More information coming soon.
In addition to the core program components, attendees will have access to the following:
- A question bank
- Recommended reading list
- Live polling, Q&A, and chat features available during the livestream days
- Chat with fellow attendees and faculty throughout the course of the meeting
Virtual Livestream Agenda
All sessions are listed in Eastern Standard Time.
- Day #1 Virtual Livestream Fri 07/24/2020
- Day #2 Virtual Livestream Fri 07/31/2020
- Day #3 Virtual Livestream Sat 08/01/2020
Welcome and HFSA Introduction
John Barnes, HFSA CEO
Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies
Immunology: The Basics, PRA, Sensitization, Crossmatch
Rejection: Cellular and Antibody Mediated
Managing Immunosuppression and Drugs
Heart Transplant, Clinical Outcomes and Complications
Hemodynamics in HF I
Hemodynamics in HF II
Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)
Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)
HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)
Management of the Hospitalized HF Patient
Management of Common Arrhythmias in HF (including AF)
Management of Comorbidities in Heart Failure
Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)
Welcome and Q&A
Cardiogenic Shock Management
MCS I: Durable MCS Devices and Outcomes
MCS II: Temporary Support Devices and ECMO for the Boards
MCS III: MCS Complications and Patient Management
MCS IV: Troubleshooting (with HARVI)
Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer
Assessment of Functional Capacity including cardiopulmonary exercise testing
Adult Congenital Heart Disease for the HF Specialist
Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)
Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)
Q&A - Overview